Résultats de recherche
27 Février 2026 - 2 mn de lecture
Listening isn’t a slogan, it’s the foundation of rare disease care
By Josep Catlla, EVP, Corporate Affairs Officer, Ipsen...
06 Février 2026 - 2 mn de lecture
Defining the path: Lineu Domit on the role of safety in early development
“Our role is to anticipate things: ‘Which dose is safe, which populations face higher risk, and how can we mitigate these risks?’”...
02 Avril 2024 - 3 mn de lecture
Unlocking Potential Through Early-Stage Partnerships
We are pleased to share a recent conversation with Mary Jane Hinrichs, Senior Vice President, and Global Head of Early Development. Mary Jane spearheads the strategic direction and execution of early-stage programs at Ipsen, guiding them from drug candidat...
20 Mai 2024 - 4 mn de lecture
Improving Diversity in Research and Development to Drive Health Equity
To mark World Clinical Trials Day, we sat down with Christelle Huguet, Executive Vice President, Head of R&D at Ipsen to explore the importance of diversity from all sides of the research and development process, as we accelerate innovation. ...
20 Mai 2024 - 5 mn de lecture
Améliorer la diversité dans la recherche et le développement pour favoriser l’équité en matière de santé
À l’occasion de la Journée internationale des essais cliniques, nous avons rencontré Christelle Huguet, Vice-Présidente Exécutive, Directrice de la Recherche et du Développement chez Ipsen, pour échanger sur la nécessité et le bénéfice d’int...
29 Juin 2022 - 6 mn de lecture
Ipsen announces U.S. FDA Priority Review for palovarotene New Drug Application in patients with fibrodysplasia ossificans progressiva following resubmission
PARIS, France, 29 June 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its resubmitted New Drug Application (NDA) for investigational palovarotene for the tre...